Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 580171, 7 pages
http://dx.doi.org/10.1155/2014/580171
Review Article

Pharmaceutical Options for Triggering of Final Oocyte Maturation in ART

1Instituto Bernabeu, Avenida Albufereta 31, 03016 Alicante, Spain
2The Fertility Clinic, Skive Regional Hospital, Faculty of Health, Aarhus University, 7800 Skive, Denmark
3Faculty of Health, University of Southern Denmark, 5230 Odense M, Denmark

Received 3 April 2014; Revised 5 June 2014; Accepted 28 June 2014; Published 15 July 2014

Academic Editor: Raúl M. Luque

Copyright © 2014 Juan Carlos Castillo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. Kessler, M. S. Reddy, R. H. Shah, and O. P. Bahl, “Structures of N-glycosidic carbohydrate units of human chorionic gonadotropin,” The Journal of Biological Chemistry, vol. 254, no. 16, pp. 7901–7908, 1979. View at Google Scholar · View at Scopus
  2. S. S. Yen, O. Llerena, B. Little, and O. H. Pearson, “Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man,” The Journal of Clinical Endocrinology and Metabolism, vol. 28, no. 12, pp. 1763–1767, 1968. View at Publisher · View at Google Scholar · View at Scopus
  3. M. D. Damewood, W. Shen, H. A. Zacur, W. D. Schlaff, J. A. Rock, and E. E. Wallach, “Disappearance of exogenously administered human chorionic gonadotropin,” Fertility and Sterility, vol. 52, no. 3, pp. 398–400, 1989. View at Google Scholar · View at Scopus
  4. R. Nakano, T. Mizuno, F. Kotsuji, K. Katayama, M. Wshio, and S. Tojo, “‘Triggering’ of ovulation after infusion of synthetic luteinizing hormone releasing factor (LRF),” Acta Obstetricia et Gynecologica Scandinavica, vol. 52, no. 3, pp. 269–272, 1973. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Diedrich, C. Diedrich, E. Santos et al., “Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation,” Human Reproduction, vol. 9, no. 5, pp. 788–791, 1994. View at Google Scholar · View at Scopus
  6. C. Albano, H. Riethmüller-Winzen, J. Smitz, A. Van Steirteghem, M. Camus, and P. Devroey, “Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation,” Fertility and Sterility, vol. 67, no. 5, pp. 917–922, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. J. D. Hoff, M. E. Quigley, and S. S. C. Yen, “Hormonal dynamics at midcycle: a reevaluation,” Journal of Clinical Endocrinology and Metabolism, vol. 57, no. 4, pp. 792–796, 1983. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Itskovitz, R. Boldes, J. Levron, Y. Erlik, L. Kahana, and J. M. Brandes, “Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist,” Fertility and Sterility, vol. 56, no. 2, pp. 213–220, 1991. View at Google Scholar · View at Scopus
  9. S. Kol, “Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome,” Fertility and Sterility, vol. 81, no. 1, pp. 1–5, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Humaidan, S. Kol, and E. G. Papanikolaou, “GnRH agonist for triggering of final oocyte maturation: time for a change of practice?” Human Reproduction Update, vol. 17, no. 4, pp. 510–524, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. B. Zelinski-Wooten, J. S. Hutchison, D. L. Hess, D. P. Wolf, and R. L. Stouffer, “Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys,” Human Reproduction, vol. 10, no. 7, pp. 1658–1666, 1995. View at Google Scholar · View at Scopus
  12. J. J. Eppig, “FSH stimulates hyaluronic acid synthesis by oocyte-cumulus cell complexes from mouse preovulatory follicles,” Nature, vol. 281, no. 5731, pp. 483–484, 1979. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Atef, P. Francois, V. Christian, and S. Marc-Andre, “The potential role of gap junction communication between cumulus cells and bovine oocytes during in vitro maturation,” Molecular Reproduction and Development, vol. 71, no. 3, pp. 358–367, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Humaidan, H. Ejdrup Bredkjær, L. G. Westergaard, and C. Yding Andersen, “1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study,” Fertility and Sterility, vol. 93, no. 3, pp. 847–854, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Oktay, I. Türkçüoǧlu, and K. A. Rodriguez-Wallberg, “GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation,” Reproductive BioMedicine Online, vol. 20, no. 6, pp. 783–788, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Parneix, J. C. Emperaire, and A. Ruffie, “Triggering of ovulation, using different regimen of gonadotropin-releasing hormone agonist,” Gynecological Endocrinology, vol. 10, supplement 1, p. 32, 1996. View at Google Scholar
  17. D. Bodri, J. J. Guillén, A. Galindo, D. Mataró, A. Pujol, and O. Coll, “Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study,” Fertility and Sterility, vol. 91, no. 2, pp. 365–371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Humaidan, N. P. Polyzos, B. Alsbjerg et al., “GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients,” Human Reproduction, vol. 28, no. 9, pp. 2511–2521, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Engmann, A. DiLuigi, D. Schmidt, J. Nulsen, D. Maier, and C. Benadiva, “The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study,” Fertility and Sterility, vol. 89, no. 1, pp. 84–91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casan, and F. Bonilla-Musoles, “Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support,” Reproductive BioMedicine Online, vol. 20, no. 2, pp. 175–181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Acevedo, J. L. Gomez-Palomares, E. Ricciarelli, and E. R. Hernández, “Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates,” Fertility and Sterility, vol. 86, no. 6, pp. 1682–1687, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Melo, C. E. Busso, J. Bellver et al., “GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study,” Reproductive BioMedicine Online, vol. 19, no. 4, pp. 486–492, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Sismanoglu, H. I. Tekin, H. F. Erden, N. H. Ciray, U. Ulug, and M. Bahceci, “Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial,” Journal of Assisted Reproduction and Genetics, vol. 26, no. 5, pp. 251–256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. C. Castillo, M. Dolz, J. Moreno et al., “Triggering with GnRH agonist in oocyte-donation cycles: oestradiol monitoring is not necessary during ovarian stimulation,” Reproductive BioMedicine Online, vol. 24, no. 2, pp. 247–250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Humaidan, H. E. Bredkjær, L. Bungum et al., “GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study,” Human Reproduction, vol. 20, no. 5, pp. 1213–1220, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. E. M. Kolibianakis, A. Schultze-Mosgau, A. Schroer et al., “A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists,” Human Reproduction, vol. 20, no. 10, pp. 2887–2892, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Engmann and C. Benadiva, “Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support,” Fertility and Sterility, vol. 97, no. 3, pp. 531–533, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Benadiva and L. Engmann, “Intensive luteal phase support after GnRH agonist trigger: it does help,” Reproductive BioMedicine Online, vol. 25, no. 3, pp. 329–330, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Humaidan, “Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study,” Reproductive BioMedicine Online, vol. 18, no. 5, pp. 630–634, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. E. G. Papanikolaou, W. Verpoest, H. Fatemi, B. Tarlatzis, P. Devroey, and H. Tournaye, “A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study,” Fertility and Sterility, vol. 95, no. 3, pp. 1174–1177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Tavaniotou and P. Devroey, “Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles,” Reproductive BioMedicine Online, vol. 13, no. 3, pp. 326–330, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. H. M. Fatemi, “The luteal phase after 3 decades of IVF: what do we know?” Reproductive Biomedicine Online, vol. 19, supplement 4, p. 4331, 2009. View at Google Scholar · View at Scopus
  33. H. M. Fatemi, B. Popovic-Todorovic, P. Donoso, E. Papanikolaou, J. Smitz, and P. Devroey, “Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors,” Reproductive BioMedicine Online, vol. 17, no. 3, pp. 307–311, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. R. G. Edwards, P. C. Steptoe, and J. M. Purdy, “Establishing full-term human pregnancies using cleaving embryos grown in vitro,” British Journal of Obstetrics and Gynaecology, vol. 87, no. 9, pp. 737–756, 1980. View at Publisher · View at Google Scholar · View at Scopus
  35. H. M. Fatemi, B. Popovic-todorovic, E. Papanikolaou, P. Donoso, and P. Devroey, “An update of luteal phase support in stimulated IVF cycles,” Human Reproduction Update, vol. 13, no. 6, pp. 581–590, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Kol, P. Humaidan, and J. Itskovitz-Eldor, “GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study,” Human Reproduction, vol. 26, no. 10, pp. 2874–2877, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Galindo, D. Bodri, J. J. Guillén, M. Colodrón, V. Vernaeve, and O. Coll, “Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial,” Gynecological Endocrinology, vol. 25, no. 1, pp. 60–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Seyhan, B. Ata, M. Polat, W. Son, H. Yarali, and M. H. Dahan, “Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG,” Human Reproduction, vol. 28, no. 9, pp. 2522–2528, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Humaidan, L. Bungum, M. Bungum, and C. Y. Andersen, “Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVFICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study,” Reproductive BioMedicine Online, vol. 13, no. 2, pp. 173–178, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Humaidan, L. H. Thomsen, and B. Alsbjerg, “GnRHa trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patients,” Human Reproduction, vol. 28, no. 9, pp. 2593–2594, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Griesinger, L. Schultz, T. Bauer, A. Broessner, T. Frambach, and S. Kissler, “Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin- releasing hormone antagonist protocol in combination with a “freeze- all” strategy: a prospective multicentric study,” Fertility and Sterility, vol. 95, no. 6, pp. 2029–2033, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Devroey, N. P. Polyzos, and C. Blockeel, “An OHSS-free clinic by segmentation of IVF treatment,” Human Reproduction, vol. 26, no. 10, pp. 2593–2597, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Mousavi Fatemi, B. Popovic-Todorovic, P. Humaidan et al., “Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone ( GnRH ) agonist trigger and “freeze-all” approach in GnRH antagonist protocol,” Fertility and Sterility, vol. 101, no. 4, pp. 1008–1011, 2014. View at Google Scholar
  44. J. C. Castillo, G. Juan, and P. Humaidan, “Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS,” Journal of Assisted Reproduction and Genetics, vol. 29, no. 3, pp. 249–253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Lok, J. Pritchard, and H. Lashen, “Successful treatment of empty follicle syndrome by triggering endogenous LH surge using GnRH agonist in an antagonist down-regulated IVF cycle,” Human Reproduction, vol. 18, no. 10, pp. 2079–2081, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. IVF Worldwide, “Survey on vitrification, GnRH trigger and differed embryo transfer,” http://www.ivf-worldwide.com/survey/vitrification-gnrhtrigger-and-differed-et.html.
  47. S. B. Seminara, S. Messager, E. E. Chatzidaki et al., “The GPR54 gene as a regulator of puberty,” The New England Journal of Medicine, vol. 349, no. 17, pp. 1614–1627, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. A. V. Schally, A. Arimura, A. J. Kastin et al., “Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones,” Science, vol. 173, no. 4001, pp. 1036–1038, 1971. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Pinilla, E. Aguilar, C. Dieguez, R. P. Millar, and M. Tena-Sempere, “Kisspeptins and reproduction: physiological roles and regulatory mechanisms,” Physiological Reviews, vol. 92, no. 3, pp. 1235–1316, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Skorupskaite, J. T. George, and R. A. Anderson, “The kisspeptins-GnRH pathway in human reproductive health and disease,” Human Reproduction Update, vol. 20, no. 4, pp. 485–500, 2014. View at Google Scholar
  51. C. N. Jayasena, G. M. K. Nijher, A. N. Comninos et al., “The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 12, pp. E1963–E1972, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. C. N. Jayasena, A. Comninos, G. Nijher et al., “Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 11, pp. 4464–4474, 2013. View at Publisher · View at Google Scholar
  53. A. Abbara, C. N. Jayasena, G. K. Nijher et al., “Kisspeptins—a novel physiological trigger for oocyte maturation in IVF treatment,” Human Reproduction; Supplement 1; European Society of Human Reproduction and Embryology 29th Annual Meeting, London,, Abstract O-107, 2013. View at Google Scholar